hyperpolarization activated cyclic nucleotide gated channels

Ivabradine hydrochloride (S 16257-2) is a new If inhibitor (IC50: 2.9 μM). Ivabradine Hydrochloride is the hydrochloride salt form of ivabradine, an orally bioavailable, hyperpolarization-activated, cyclic nucleotide-gated (HCN) channel blocker, with negative chronotropic activity. Upon administration, ivabradine selectively binds to the intracellular portion of the HCN channel pore and blocks HCN channels in the pacemaker cells within the sinoatrial (SA) node. This inhibits the If (funny) pacemaker ion current, prevents the inward flow and intracellular accumulation of positively charged ions, reduces pacemaker activity and slows diastolic depolarization.

ZD7288 (ICI D7288), a selective hyperpolarization-activated cyclic nucleotide-gated channel blocker, inhibits hippocampal synaptic plasticity.

Zatebradine is a potent hyperpolarization-activated cyclic nucleotide-gated (HCN) channels inhibitor(IC50 of 1.96 µM).

MS7710 is a brain-penetrant inhibitor of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. It reduces Ih current by inhibiting HCN channels, thereby decreasing the activity of dopamine neurons in the ventral tegmental area (VTA). MS7710 effectively improves social interaction deficits and reward-related cognitive flexibility in mouse models of chronic social defeat stress (CSDS) and shows promise for depression research.

Ivabradine Impurity 2, an impurity of Ivabradine, is a compound known for its oral bioavailability and mechanism as a blocker of hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels [1].

Ivabradine hydrochloride (Standard) is a reference standard for research and analysis in studies involving Ivabradine hydrochloride. Ivabradine hydrochloride (S 16257-2) is a new If inhibitor (IC50: 2.9 μM). Ivabradine Hydrochloride is the hydrochloride salt form of ivabradine, an orally bioavailable, hyperpolarization-activated, cyclic nucleotide-gated (HCN) channel blocker, with negative chronotropic activity. Upon administration, ivabradine selectively binds to the intracellular portion of the HCN channel pore and blocks HCN channels in the pacemaker cells within the sinoatrial (SA) node. This inhibits the If (funny) pacemaker ion current, prevents the inward flow and intracellular accumulation of positively charged ions, reduces pacemaker activity and slows diastolic depolarization.